Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte, Inc. (Nasdaq: VCYT) presented new data at the 2022 ASCO GU Symposium confirming the efficacy of the Decipher Prostate Genomic Classifier for prostate cancer treatment selection. This Phase 3 study validates the Classifier's role as a prognostic biomarker for men with intermediate-risk prostate cancer, providing critical insights for personalized treatment. Key findings indicate that patients classified as Decipher ‘high-risk’ have significantly worse clinical outcomes compared to ‘low-risk’ patients. This innovative approach could greatly enhance treatment strategies for prostate cancer patients.
Veracyte (Nasdaq: VCYT) announced that CEO Marc Stapley and CFO Rebecca Chambers will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 2:20 p.m. Eastern Time. A live audio webcast of the presentation will be available on Veracyte’s website, with a replay accessible for 90 days afterward. Veracyte specializes in diagnostics, offering tests for various cancers and other diseases, utilizing genomic advancements to enhance patient care.
Veracyte (NASDAQ: VCYT) announced the presentation of six abstracts at the 2022 ASCO GU Cancers Symposium, occurring from February 17-19, 2022. The studies focus on the Decipher genomic classifier as a prognostic biomarker for intermediate-risk prostate cancer, marking a significant late-stage validation of gene expression classifiers. The presentations will share insights on risk stratification and treatment guidance for urologic cancers.
The event takes place in location value="LU/us.ca.sanfrn"San Francisco, Calif..
Summary not available.
Veracyte (NASDAQ: VCYT) has announced significant leadership promotions aimed at enhancing its strategic vision in diagnostics. Tina Nova, Ph.D., is appointed president of the CLIA U.S. business, while Stephane Debono becomes general manager for IVD and EMEA organizations. Giulia C. Kennedy, Ph.D., is named global chief scientific officer and chief medical officer. These appointments are expected to align Veracyte's operations and bolster its market presence. The company focuses on developing innovative diagnostic tests to address unmet clinical needs, ultimately improving patient outcomes globally.
Veracyte, Inc. (NASDAQ: VCYT) released clinical data supporting the Envisia Genomic Classifier's role in enhancing diagnostic and treatment processes for patients with idiopathic pulmonary fibrosis (IPF). The findings, published in the Annals of the American Thoracic Society, demonstrate a significant increase in IPF diagnoses (39%) and physician confidence (36.2%) post-Envisia application. The study emphasizes reduced reliance on invasive procedures while promoting timely treatment recommendations, with potential benefits for approximately 200,000 patients annually in the U.S. and Europe.
Veracyte, Inc. (NASDAQ: VCYT) announced the Swedish Medical Technologies Product Council's recommendation for the Prosigna Breast Cancer Assay, enabling immediate reimbursement across all Swedish healthcare regions as of November 22, 2021. This marks a significant advancement following its prior approval in Germany, solidifying Prosigna's reimbursement momentum in the EU. The assay aids in chemotherapy decisions for women over 50 with specific breast cancer types, ensuring access without legal restrictions.
Veracyte (NASDAQ: VCYT) announced new data from three posters presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, showcasing the potential of Brightplex technology in immuno-oncology. This technology assesses the tumor micro-environment and aids in designing effective immunotherapies. Notably, findings from the PIONeeR project suggest that the Brightplex TCE assay can stratify non-small cell lung cancer patients into four subtypes, potentially predicting outcomes based on T-cell densities. This innovation positions Veracyte favorably in advancing cancer treatment.
Veracyte reported a 94% increase in total revenue to $60.4 million for Q3 2021, aided by its HalioDx acquisition. The company launched its innovative Percepta Nasal Swab and Decipher Bladder genomic tests amidst COVID-19 challenges. Despite growing revenues, Veracyte's operating expenses surged 123%, leading to a net loss of $14.1 million, a 243% increase year-over-year. The updated 2021 revenue guidance ranges from $210 million to $218 million, projecting 79% to 86% growth compared to 2020.
Veracyte (Nasdaq: VCYT) announced the inclusion of its Immunoscore Colon Cancer test in the new Pan-Asian ESMO Clinical Practice Guidelines for localized colon cancer diagnosis and treatment. The test, acquired through HalioDx in August 2021, assesses patient immune response and aids chemotherapy decisions for Stage II and III colon cancer patients. With increasing colorectal cancer cases in Asia, this recognition by Pan-Asian experts is a significant milestone, potentially facilitating wider reimbursement and patient access to the test.